Keystone Financial Planning’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.83M Sell
242,093
-4,289
-2% -$112K 1.5% 17
2026
Q1
$6.92M Hold
246,382
1.85% 13
2025
Q4
$6.13M Sell
246,382
-7,583
-3% -$191K 1.78% 15
2025
Q3
$6.47M Sell
253,965
-890
-0.3% -$22K 1.88% 14
2025
Q2
$6.18M Sell
254,855
-1,332
-0.5% -$31.1K 1.87% 13
2025
Q1
$6.49M Hold
256,187
1.93% 16
2024
Q4
$6.8M Sell
256,187
-512
-0.2% -$13.9K 2.11% 12
2024
Q3
$7.43M Sell
256,699
-211
-0.1% -$6.16K 2.25% 9
2024
Q2
$7.19M Sell
256,910
-265
-0.1% -$7.3K 2.38% 7
2024
Q1
$7.14M Sell
257,175
-8,238
-3% -$229K 2.31% 12
2023
Q4
$7.64M Buy
265,413
+19,537
+8% +$591K 2.52% 7
2023
Q3
$8.16M Buy
245,876
+13,630
+6% +$482K 2.85% 3
2023
Q2
$8.52M Buy
232,246
+14,231
+7% +$554K 2.85% 4
2023
Q1
$8.89M Buy
218,015
+162,376
+292% +$7.01M 3.03% 4
2022
Q4
$2.85M Sell
55,639
-313
-0.6% -$15K 0.96% 27
2022
Q3
$2.45M Sell
55,952
-8,098
-13% -$394K 0.94% 27
2022
Q2
$3.36M Buy
64,050
+8,553
+15% +$436K 1.18% 28
2022
Q1
$2.87M Buy
55,497
+531
+1% +$27.6K 0.96% 31
2021
Q4
$3.25M Sell
54,966
-176,640
-76% -$8.75M 1.11% 29
2021
Q3
$9.96M Sell
231,606
-5,780
-2% -$256K 3.62% 3
2021
Q2
$9.3M Sell
237,386
-3,144
-1% -$122K 3.37% 5
2021
Q1
$8.71M Buy
240,530
+5,223
+2% +$185K 3.25% 9
2020
Q4
$8.66M Sell
235,307
-5,511
-2% -$202K 3.59% 2
2020
Q3
$8.38M Buy
240,818
+1,997
+0.8% +$70K 4.05% 2
2020
Q2
$7.41M Buy
238,821
+3,390
+1% +$115K 3.65% 9
2020
Q1
$7.29M Buy
235,431
+9,451
+4% +$322K 4.17% 3
2019
Q4
$8.4M Buy
225,980
+7,327
+3% +$261K 3.75% 5
2019
Q3
$7.45M Buy
218,653
+8,308
+4% +$302K 3.56% 7
2019
Q2
$8.64M Sell
210,345
-327
-0.2% -$13K 4.23% 3
2019
Q1
$8.49M Buy
210,672
+1,630
+0.8% +$65.3K 4.19% 2
2018
Q4
$8.66M Buy
209,042
+603
+0.3% +$25K 4.84% 1
2018
Q3
$8.71M Sell
208,439
-5,554
-3% -$214K 4.45% 2
2018
Q2
$7.37M Buy
213,993
+1,454
+0.7% +$49.7K 4.06% 4
2018
Q1
$7.16M Buy
212,539
+6,781
+3% +$233K 3.99% 4
2017
Q4
$7.07M Buy
205,758
+2,361
+1% +$80.5K 3.77% 8
2017
Q3
$6.89M Buy
203,397
+5,720
+3% +$184K 3.91% 5
2017
Q2
$6.3M Buy
197,677
+6,051
+3% +$191K 3.82% 4
2017
Q1
$6.22M Buy
191,626
+3,279
+2% +$103K 3.87% 6
2016
Q4
$5.8M Buy
188,347
+3,455
+2% +$105K 3.79% 6
2016
Q3
$5.94M Buy
184,892
+2,582
+1% +$86.3K 3.9% 5
2016
Q2
$6.09M Buy
182,310
+3,207
+2% +$102K 4.12% 5
2016
Q1
$5.04M Buy
179,103
+5,392
+3% +$154K 3.61% 8
2015
Q4
$5.32M Buy
173,711
+166
+0.1% +$5.22K 4.03% 7
2015
Q3
$5.17M Buy
173,545
+409
+0.2% +$13.1K 4.18% 3
2015
Q2
$5.51M Buy
173,136
+229
+0.1% +$7.46K 4.22% 3
2015
Q1
$5.71M Buy
172,907
+879
+0.5% +$27.9K 4.34% 3
2014
Q4
$5.08M Buy
172,028
+8,464
+5% +$243K 3.75% 9
2014
Q3
$4.59M Buy
163,564
+6
+0% +$168 3.46% 12
2014
Q2
$4.61M Sell
163,558
-783
-0.5% -$22.3K 3.47% 15
2014
Q1
$5.01M Buy
164,341
+3,691
+2% +$110K 3.88% 4
2013
Q4
$4.67M Buy
+160,650
New +$4.68M 3.73% 3

Other funds holding PFE

Keystone Financial Planning's PFE Position: Q2 2026 in Review

Keystone Financial Planning reduced its Pfizer (PFE) stake by 1.7% in Q2 2026, selling an estimated $112K and leaving 242,093 shares worth $5.83M. The position accounts for 1.5% of the portfolio, ranked #17.

Keystone Financial Planning first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $9.96M in Q3 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Keystone Financial Planning held 242,093 shares of Pfizer worth $5.83M as of Q2 2026.
  • Keystone Financial Planning sold 4,289 Pfizer shares in Q2 2026, an estimated $112K.
  • Pfizer made up 1.5% of Keystone Financial Planning's portfolio in Q2 2026, its #17 holding.
  • Keystone Financial Planning first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
  • Keystone Financial Planning's Pfizer position peaked at $9.96M in Q3 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Keystone Financial Planning's 13F filing for Q2 2026, filed 15 Jul 2026.